STOCK TITAN

Evelo Biosciences to Report Fourth Quarter and Full Year 2020 Financial Results on Tuesday, March 9, 2021

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences earnings
Rhea-AI Summary

Evelo Biosciences (Nasdaq:EVLO), a clinical stage biotechnology firm, will host a conference call on March 9, 2021, at 8:30 a.m. ET to report its fourth quarter and full year 2020 financial results. The event will showcase business highlights and can be accessed via dial-in or a live webcast on their website. Evelo focuses on developing orally delivered therapies targeting inflammatory diseases and cancer, with four product candidates in the pipeline, including EDP1815 and EDP1908.

Positive
  • Evelo is advancing four product candidates targeting inflammatory diseases and cancer, indicating potential growth.
  • The live conference call may provide crucial insights into the company's financial health and future outlook.
Negative
  • None.

CAMBRIDGE, Mass., March 02, 2021 (GLOBE NEWSWIRE) -- Evelo Biosciences (Nasdaq:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered medicines, today announced that it will host a conference call and live webcast at 8:30 a.m. ET on Tuesday, March 9, 2021 to report its fourth quarter and full year 2020 financial results and discuss business highlights.

To access the live conference call, please dial 866-795-3242 (domestic) or 409-937-8909 (international) and refer to conference ID 3094547. A live webcast of the event will also be available under “News and Events” in the Investors section of Evelo's website at http://ir.evelobio.com. The archived webcast will be available on Evelo's website approximately two hours after the completion of the event and will be available for 30 days following the call.

About Evelo Biosciences
Evelo Biosciences is a clinical stage biotechnology company developing orally delivered product candidates that are designed to act on SINTAX with systemic therapeutic effects. SINTAX plays a central role in governing the immune, metabolic, and neurological systems. The Company’s first product candidates are pharmaceutical preparations of single strains of microbes selected for the potential to offer defined pharmacological properties. Evelo’s therapies have the potential to be effective, safe, and affordable medicines to improve the lives of people with inflammatory diseases and cancer.

Evelo currently has four product candidates in development: EDP1815, EDP1867, and EDP2939 for the treatment of inflammatory diseases and EDP1908 for the treatment of cancer. Evelo is advancing additional product candidates in other disease areas.

For more information, please visit www.evelobio.com and engage with Evelo on LinkedIn.

Contact
Jessica Cotrone, 978-760-5622
jcotrone@evelobio.com


FAQ

When will Evelo Biosciences report its Q4 and full year 2020 financial results?

Evelo Biosciences will report its Q4 and full year 2020 financial results on March 9, 2021.

What is Evelo Biosciences focusing on in its product development?

Evelo Biosciences is developing orally delivered therapies aimed at treating inflammatory diseases and cancer.

How can I access the live conference call for Evelo Biosciences?

The live conference call can be accessed by dialing 866-795-3242 for domestic or 409-937-8909 for international callers.

What are the names of Evelo's product candidates?

Evelo's product candidates include EDP1815, EDP1867, EDP2939 for inflammatory diseases, and EDP1908 for cancer.

EVELO BIOSCIENCES INC

OTC:EVLO

EVLO Rankings

EVLO Latest News

EVLO Stock Data

958.63k
18.86M
0.14%
13.16%
1.04%
Biotechnology
Healthcare
Link
United States of America
Cambridge